TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35418039

Group type: EXPERIMENTAL
Intervention: Support for legalization of unspecified living kidney donation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Acceptance of family member donating to a stranger
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Belief that bone-marrow transplant is safe
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Recognition of benefits of pre-donation tests
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Willingness to receive a kidney from another person
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Willingness to donate organs after death
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fear of organ trafficking
Number of subjects: 62
Study: 35418107

Group type: EXPERIMENTAL
Intervention: Mailed fecal testing outreach and patient navigation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 35418154

Group type: EXPERIMENTAL
Intervention: Watch antibiotics (e.g., ceftriaxone, ciprofloxacin)
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Watch antibiotics
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Access antibiotics
Number of subjects: 920
Study: 35418159

Group type: EXPERIMENTAL
Intervention: C1M (serum type I collagen degradation biomarker)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: C1M in obese asthmatics (BMI > 30) with high neutrophil levels
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: C1M in OVA mice with acute neutrophilic inflammation
Number of subjects: 233

Group type: COMPARATOR
Intervention: C1M in mice treated with CP17 (neutrophil infiltration inhibitor)
Number of subjects: 233
Study: 35418172

Group type: EXPERIMENTAL
Intervention: abatacept (ABA) + MTX
Number of subjects: 509

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 509
Study: 35418195

Group type: EXPERIMENTAL
Intervention: PD-L1highICOSLlow Secretory DCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PD-L1lowICOSLhigh Helper DCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secretory DCs
Number of subjects: 0
Study: 35418260

Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 1643
Study: 35418329

Group type: EXPERIMENTAL
Intervention: Vaginal pH modulator (VPM; Phexxi)
Number of subjects: 1330
Study: 35418339

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied over three different sites in the dorsolateral prefrontal cortex
Number of subjects: 15

Group type: COMPARATOR
Intervention: General linear model (GLM) analysis
Number of subjects: 15
Study: 35418436

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine awareness and acceptance
Number of subjects: 4198

Group type: EXPERIMENTAL
Intervention: Perceived effectiveness and safety of COVID-19 vaccines
Number of subjects: 4198

Group type: EXPERIMENTAL
Intervention: Sociodemographic factors
Number of subjects: 4198
Study: 35418459

Group type: EXPERIMENTAL
Intervention: Higher physical activity
Number of subjects: 134
Study: 35418509

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 65
Study: 35418586

Group type: EXPERIMENTAL
Intervention: Wearing face masks
Number of subjects: 6925

Group type: EXPERIMENTAL
Intervention: Standard wearing of face masks
Number of subjects: 6925

Group type: EXPERIMENTAL
Intervention: Nonstandard wearing of face masks, longer time of face mask wearing, reduced outdoor time, decreased daily reading time, shortened visual display terminals time, dry environment
Number of subjects: 6925

Group type: EXPERIMENTAL
Intervention: Age, female sex, education, use of glasses and contact lenses, pre-existing dry eye
Number of subjects: 6925

Group type: EXPERIMENTAL
Intervention: Adults aged > 20 years
Number of subjects: 6925
Study: 35418936

Group type: EXPERIMENTAL
Intervention: Shunt surgery
Number of subjects: 127

Group type: COMPARATOR
Intervention: Physical exercise program
Number of subjects: 127
Study: 35419605

Group type: EXPERIMENTAL
Intervention: Early infant probiotic supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35419649

Group type: EXPERIMENTAL
Intervention: Everolimus and Sunitinib
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual pNET treatments (chemotherapies and somatostatin analogues)
Number of subjects: 144
Study: 35419748

Group type: EXPERIMENTAL
Intervention: Perfusion CT and dual-energy CT (DECT) quantitative parameters
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Permeability surface-area product (PS)
Number of subjects: 56
Study: 35420493

Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBP-PI-HBr); specific dosage and duration not mentioned.
Number of subjects: 0
Study: 35420578

Group type: EXPERIMENTAL
Intervention: Exercise training (8 weeks of intensive aerobic cycle training)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pannexin 1 inhibition after training
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 27
Study: 35420586

Group type: EXPERIMENTAL
Intervention: Nonimprovement group (n = 92)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Improvement group (n = 38)
Number of subjects: 148
Study: 35420628

Group type: EXPERIMENTAL
Intervention: Cabozantinib, 60 mg orally once daily until disease progression, unacceptable toxic effects, or withdrawal of consent.
Number of subjects: 23
Study: 35420700

Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions
Number of subjects: 8186
Study: 35421002

Group type: EXPERIMENTAL
Intervention: Jarvik 2000 device
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cone-bearing group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 150
Study: 35421085

Group type: EXPERIMENTAL
Intervention: Machine Learning models using interview variables
Number of subjects: 1694

Group type: EXPERIMENTAL
Intervention: Machine Learning models using complementary exam variables
Number of subjects: 1694

Group type: EXPERIMENTAL
Intervention: Machine Learning models using mixed variables (interview and complementary exams)
Number of subjects: 1694
Study: 35421219

Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Number of subjects: 103
Study: 35421228

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for ≤2 years
Number of subjects: 51
Study: 35421231

Group type: EXPERIMENTAL
Intervention: HepaVac-101 (IMA970A and CV8102)
Number of subjects: 22
Study: 35421287

Group type: EXPERIMENTAL
Intervention: Digital medicine system, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 35421548

Group type: EXPERIMENTAL
Intervention: Injured knees
Number of subjects: 118

Group type: COMPARATOR
Intervention: Uninjured knees (contralateral knees)
Number of subjects: 118
Study: 35421930

Group type: EXPERIMENTAL
Intervention: High degree-of-worry
Number of subjects: 2857

Group type: COMPARATOR
Intervention: Low degree-of-worry
Number of subjects: 2857

Group type: EXPERIMENTAL
Intervention: Parental degree-of-worry scoring
Number of subjects: 2857
Study: 35421962

Group type: EXPERIMENTAL
Intervention: Viniyoga, an individualized Yoga practice for 14 weeks
Number of subjects: 21
Study: 35421966

Group type: EXPERIMENTAL
Intervention: Yathu Yathu intervention (community-based, peer-led SRH services including differentiated HTS and CSE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social media (WhatsApp/Facebook) for delivering CSE and COVID-19 information
Number of subjects: 0
Study: 35422096

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 16
Study: 35422132

Group type: EXPERIMENTAL
Intervention: CHW-delivered intervention
Number of subjects: 255
Study: 35422242

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 702

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 702
Study: 35422531

Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 152
Study: 35422607

Group type: COMPARATOR
Intervention: Intravitreal aflibercept injections (IVT-AFL) with sham laser
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (IVT-AFL) with micropulse (MP) laser
Number of subjects: 30
Study: 35422656

Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (RT)
Number of subjects: 12500
Study: 35425788

Group type: EXPERIMENTAL
Intervention: DHA (800 mg/day) and EPA (25 mg/day) supplementation for 6 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 35425819

Group type: EXPERIMENTAL
Intervention: Increased percentage of REM sleep (per 5%)
Number of subjects: 4490

Group type: EXPERIMENTAL
Intervention: Total REM sleep time
Number of subjects: 4490
Study: 35425895

Group type: EXPERIMENTAL
Intervention: Adapted fencing program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 35425930

Group type: EXPERIMENTAL
Intervention: Ketogenic diet combined with cytotoxic chemotherapy (nab-paclitaxel, gemcitabine, cisplatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard high-carbohydrate diet combined with cytotoxic chemotherapy (nab-paclitaxel, gemcitabine, cisplatin)
Number of subjects: 0
Study: 35425934

Group type: EXPERIMENTAL
Intervention: Smart-T2 intervention (smartphone-based just-in-time adaptive intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TTRP intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: QuitGuide intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smart-T2 intervention
Number of subjects: 0
Study: 35425938

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35425985

Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg once daily added to stable combined ART for 5 days
Number of subjects: 8
Study: 35426046

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim OBI
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Other options (other G-CSF or none)
Number of subjects: 1776
Study: 35426404

Group type: EXPERIMENTAL
Intervention: Risk-score model for lymph node metastases (LN+) based on variables such as age, tumor location, tumor grade, tumor size, and lymphovascular invasion.
Number of subjects: 12228
Study: 35426405

Group type: EXPERIMENTAL
Intervention: Biologic, degradable extracellular matrix (ECM)
Number of subjects: 66
Study: 35426524

Group type: EXPERIMENTAL
Intervention: Nutritional impact symptoms (NIS)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Total cumulative NIS
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Factors increasing risk for body weight loss
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Body weight loss
Number of subjects: 197
Study: 35426735

Group type: EXPERIMENTAL
Intervention: Standardized Soft Tissue Mobilization
Number of subjects: 0
Study: 35426861

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 157
Study: 35427700

Group type: EXPERIMENTAL
Intervention: MANTA VCD (Teleflex/Essential Medical Inc.)
Number of subjects: 1000
Study: 35427703

Group type: EXPERIMENTAL
Intervention: CAVS families with TAV and BAV probands
Number of subjects: 2371

Group type: COMPARATOR
Intervention: Control families screened for BAV
Number of subjects: 2371
Study: 35427833

Group type: EXPERIMENTAL
Intervention: Pembrolizumab and maraviroc
Number of subjects: 20

Group type: COMPARATOR
Intervention: Poststudy salvage treatment
Number of subjects: 20
Study: 35428207

Group type: EXPERIMENTAL
Intervention: Sn-117 m-DTPA
Number of subjects: 25
Study: 35428211

Group type: EXPERIMENTAL
Intervention: IV injection of low activity benzamide-based radioligands targeting melanin
Number of subjects: 0
Study: 35428230

Group type: EXPERIMENTAL
Intervention: Malaria self-management kits distributed after training to gold miners.
Number of subjects: 0
Study: 35428256

Group type: EXPERIMENTAL
Intervention: Quality of rehabilitation processes measured by 11 process indicators (pass rates from 0 to 100%) after 2 months.
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Goal attainment measured by Patient-Specific Functional Scale.
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Physical function measured by 30 s sit-to-stand test.
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Health-related quality of life measured by EuroQoL 5D-5L.
Number of subjects: 293
Study: 35428289

Group type: EXPERIMENTAL
Intervention: Co-created multi-component physical activity interventions in nursing care
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Co-created multi-component physical activity interventions in automotive mechatronics
Number of subjects: 111

Group type: COMPARATOR
Intervention: Co-created multi-component physical activity interventions
Number of subjects: 111
Study: 35428342

Group type: EXPERIMENTAL
Intervention: Practice facilitation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Self-directed control (receipt of TASSH with no practice facilitation)
Number of subjects: 29
Study: 35428346

Group type: EXPERIMENTAL
Intervention: Dual-tDCS during physical therapy (2 mA for 20 minutes)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Before stimulation protocol (previous study)
Number of subjects: 19
Study: 35428353

Group type: EXPERIMENTAL
Intervention: ICPtcd (Transcranial Doppler)
Number of subjects: 262
Study: 35428480

Group type: EXPERIMENTAL
Intervention: Hysteroscopic sterilization
Number of subjects: 29871

Group type: COMPARATOR
Intervention: Laparoscopic sterilization
Number of subjects: 29871
Study: 35428649

Group type: EXPERIMENTAL
Intervention: CT imaging for staging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging for staging
Number of subjects: 0
Study: 35428657

Group type: EXPERIMENTAL
Intervention: Autologous, ex vivo expanded Tregs infusion (1×10^6 cells)
Number of subjects: 1
Study: 35428655

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione usage
Number of subjects: 30
Study: 35428708

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 170
Study: 35428884

Group type: EXPERIMENTAL
Intervention: Lonapegsomatropin
Number of subjects: 0

Group type: COMPARATOR
Intervention: TransCon hGH Auto-Injector
Number of subjects: 0
Study: 35428916

Group type: EXPERIMENTAL
Intervention: GAP score parameters
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Relative lumbar lordosis 15 degrees greater than ideal lumbar lordosis
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Lumbar distribution index of 90%
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Age-adjusted offset alignment targets
Number of subjects: 165
Study: 35429109

Group type: EXPERIMENTAL
Intervention: FI-35
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: FTS-5
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: FRAIL scale
Number of subjects: 996
Study: 35429115

Group type: EXPERIMENTAL
Intervention: Circulating proteins related to adipokine signaling and vascular function (e.g., leptin, vascular endothelial growth factor) in women
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Circulating proteins related to extracellular matrix organization and inflammation (e.g., matrix metalloproteinase-2, C-reactive protein) in men
Number of subjects: 399

Group type: COMPARATOR
Intervention: Association with cardiovascular outcomes
Number of subjects: 399
Study: 35429329

Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg daily), Dexamethasone (20-40 mg weekly), Daratumumab (16 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pomalidomide, Dexamethasone, Daratumumab
Number of subjects: 18
Study: 35429387

Group type: EXPERIMENTAL
Intervention: Early chronotype
Number of subjects: 34
Study: 35429391

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) and Carboplatin (target AUC 6) intravenously every 3 weeks for up to 6 cycles
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin chemotherapy
Number of subjects: 16
Study: 35429903

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35430299

Group type: EXPERIMENTAL
Intervention: anti-PD-1 therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination immunotherapy for HCC
Number of subjects: 32
Study: 35430328

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 35430710

Group type: EXPERIMENTAL
Intervention: Clinical decision aid for midfacial trauma
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: Clinical decision aid for mandibular trauma
Number of subjects: 993
Study: 35430801

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to the primary motor cortex of the lesioned hemisphere, combined with standardized rehabilitative training, applied in 10 sessions over 2 weeks.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (1:1 randomization)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 120
Study: 35431132

Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine delivery via TAR-200 (two 7-day cycles)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine delivery via TAR-200 (Arm 1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine delivery via TAR-200 (Arm 2)
Number of subjects: 23
Study: 35431240

Group type: EXPERIMENTAL
Intervention: SCD individuals (Aβ positive)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: SCD individuals (Aβ negative)
Number of subjects: 668

Group type: COMPARATOR
Intervention: SCD individuals
Number of subjects: 668
Study: 35431355

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Number of subjects: 50
Study: 35431559

Group type: EXPERIMENTAL
Intervention: Positive skin prick tests (SPT)
Number of subjects: 11283
Study: 35431895

Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation (dDBS) targeting the fornix, stimulation parameters set between 3.9 and 7.5 mA, 90 μs, 130 Hz for 24 months.
Number of subjects: 1
Study: 35431912

Group type: EXPERIMENTAL
Intervention: Psilocybin Assisted Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 35431953

Group type: EXPERIMENTAL
Intervention: ACT-1004-1239
Number of subjects: 0
Study: 35432163

Group type: EXPERIMENTAL
Intervention: Prism Adaptation Treatment (PAT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Alternative therapies (Control)
Number of subjects: 37
Study: 35432170

Group type: EXPERIMENTAL
Intervention: VIP (8 pmol/kg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 0
Study: 35432194

Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 35
Study: 35432352

Group type: EXPERIMENTAL
Intervention: Anti-CD30 CAR-T therapy combined with PD-1 inhibitor
Number of subjects: 7

Group type: COMPARATOR
Intervention: Lymphocyte-depleting chemotherapy with fludarabine and cyclophosphamide
Number of subjects: 7
Study: 35432994

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 49
Study: 35433325

Group type: EXPERIMENTAL
Intervention: Western Aphasia Battery-Revised
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Barthel Index
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neuropsychiatric Inventory
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Domain-specific scales (Stroke Aphasia Depression Questionnaire-10 item version, Starkstein Apathy Scale)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adapted version of the Hospital Anxiety and Depression Scale
Number of subjects: 20
Study: 35433488

Group type: EXPERIMENTAL
Intervention: PAM50 classification (LumA, LumB, HER2E, Basal)
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: PAM50-derived risk of recurrence
Number of subjects: 1071

Group type: EXPERIMENTAL
Intervention: Transcriptomic pathway analysis
Number of subjects: 1071

Group type: COMPARATOR
Intervention: Traditional subtypes (HR, HER2, Ki67)
Number of subjects: 1071
Study: 35433544

Group type: EXPERIMENTAL
Intervention: Eczema (with or without a positive skin prick test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eczema
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eczema and ADHD
Number of subjects: 0
Study: 35433774

Group type: EXPERIMENTAL
Intervention: Probiotic intake (from yoghurts or dietary supplements)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Ordinary yoghurt intake
Number of subjects: 888

Group type: COMPARATOR
Intervention: No yoghurt intake
Number of subjects: 888
Study: 35433861

Group type: EXPERIMENTAL
Intervention: Jailed Balloon Technique (JBT)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Jailed Wire Technique (JWT)
Number of subjects: 284
Study: 35433879

Group type: EXPERIMENTAL
Intervention: PRIME score (machine learning-based model)
Number of subjects: 220

Group type: COMPARATOR
Intervention: EuroSCORE II (traditional risk model)
Number of subjects: 220
Study: 35433884

Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 2356

Group type: COMPARATOR
Intervention: Non-Chronic Kidney Disease (non-CKD)
Number of subjects: 2356
Study: 35434343

Group type: EXPERIMENTAL
Intervention: Pembrolizumab given 2-3 weeks prior to chemoradiation and then, q21 days concurrently with high-dose cisplatin and radiation prescribed to a total dose of 70 Gy.
Number of subjects: 9
Study: 35434451

Group type: EXPERIMENTAL
Intervention: Abaloparatide (ABL) followed by Alendronate (ALN) for 18 months and 24 months respectively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PBO) followed by Alendronate (ALN)
Number of subjects: 0
Study: 35434588

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 17
Study: 35434590

Group type: EXPERIMENTAL
Intervention: Metabolomic analysis of serum samples using mass spectrometry
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Analysis of circulating metabolites
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Identification of metabolic transition point
Number of subjects: 627
Study: 35434696

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 1589

Group type: EXPERIMENTAL
Intervention: Rehospitalization or death after hospital discharge
Number of subjects: 1589
Study: 35434725

Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg daily, titrated to 800 mg)
Number of subjects: 940

Group type: COMPARATOR
Intervention: Febuxostat (40 mg daily, titrated to 120 mg)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Allopurinol and Febuxostat (both treatments)
Number of subjects: 940